United States v. Callanish Ltd.

34 Ct. Int'l Trade 1423, 2010 CIT 124
CourtUnited States Court of International Trade
DecidedNovember 2, 2010
DocketCourt 03-00658
StatusPublished

This text of 34 Ct. Int'l Trade 1423 (United States v. Callanish Ltd.) is published on Counsel Stack Legal Research, covering United States Court of International Trade primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Callanish Ltd., 34 Ct. Int'l Trade 1423, 2010 CIT 124 (cit 2010).

Opinion

*1424 OPINION AND ORDER

STANCEU, Judge:

Following the court’s opinion and order in United States v. Scotia Pharmaceuticals Ltd., 33 CIT _, Slip Op. 09-49 (May 20, 2009), plaintiff filed an amended complaint to recover a civil penalty under Section 592 of the Tariff Act of 1930, as amended, 19 U.S.C. § 1592 (1988) (“Section 592”) against defendant Callanish Ltd. (“Callanish”) in the amount of $17,734,926. Am. Compl. ¶¶ 91-93. Plaintiff’s claim arises out of fifty-two consumption entries of merchandise, made between September 1, 1988 and March 24, 1992, that plaintiff alleges to have been capsules of “evening primrose oil” (“EPO”), a substance used as a food additive that could not be imported lawfully at the time of the entries at issue. Id. ¶¶ 11-12, 91-93. After defendant failed to appear by licensed counsel and failed to plead or otherwise defend itself within twenty days of being served with the summons and the amended complaint, the Clerk of this Court, pursuant to USCIT Rules 12 and 55, entered Callanish’s default. Entry of Default 1.

On May 19, 2010, plaintiff applied for a judgment by default against Callanish in the amount of $17,734,926 pursuant to USCIT Rule 55(b). Pl.’s Req. for Default J. as to Callanish Ltd. 1-2 (“Pl.’s Req. for Default J.”). Upon review of the amended complaint and plaintiff’s application, the court holds that plaintiff has not established its entitlement to the default judgment it seeks against Callanish because plaintiff has failed to set forth as a well-pled fact the domestic value of the merchandise plaintiff alleges to have been imported fraudulently. The court, therefore, will deny without prejudice plaintiff’s application for a default judgment.

I. Background

A. Alleged Fraudulent Scheme to Unlawfully Import Evening Primrose Oil

The amended complaint alleges that beginning on February 12, 1985, the Food and Drug Administration (“FDA”) issued a series of import alerts announcing that evening primrose oil coüld not be sold lawfully in the United States without FDA approval, that this substance did not have FDA approval, and that all import shipments of EPO offered for entry into the United States were to be detained by Customs and Border Protection (“Customs”) and naming Efamol Research, Inc. as a seller of EPO. Am. Compl. ¶ 5; Pl.’s Req. for Default J. 5; Admin. R. Doc. Nos. 70-75.

The amended complaint further alleges that during the period from September 1, 1988 to March 24, 1992, Callanish introduced, or aided and abetted another to enter or introduce, into the United States *1425 merchandise consisting of capsules of EPO under cover of fifty-two consumption entries filed at various ports of entry throughout the United States by means of material and false acts, statements and/or material omissions, in violation of Section 592. Am. Compl. ¶¶ 11-12, 91-93; Admin. R. Doc. Nos. 1-12 (Declaration of Timothy F. Quinn, Special Agent, U.S. Immigration and Customs Enforcement).

Plaintiff identifies several main participants in the alleged fraudulent scheme: (1) Murdock Healthcare, “the real buyer and importer” (a U.S. company doing business under several names such as Health Products International (“HPI”)); 1 (2) Chester Lockard, the “straw buyer and importer of record” in the United States who served as president of the two U.S. companies, Pine Lawn Farms, Inc., and Genesis II of Mid-America, that paid the duties and fees for EPO shipments and then billed HPI for the shipments, plus commission; 2 and (3) three subsidiaries of Scotia Pharmaceuticals Ltd. (“Scotia Pharmaceuticals”), a British company: Efamol Ltd. (the British distributor of EPO), Efamol Research, Inc., the successor of which is Quantanova, Canada, Ltd. (“Quantanova”), and defendant Callanish, a British corporation with a business address at Breasclete, Isle of Lewis, Scotland, United Kingdom, that manufactured and shipped the EPO to the United States. Am. Compl. ¶¶ 6-10; Pl.’s Req. for Default J. 3-4.

Specifically, plaintiff alleges that Callanish, as the party responsible for shipping each of the fifty-two entries of EPO to the United States, performed the following acts in furtherance of the fraudulent scheme: (1) “Callanish followed HPI’s instructions to ship the EPO . .

. and not to list or describe the merchandise as EPO;” (2) “Callanish provided false invoices to HPI showing the buyer as Pine Lawn Farms rather than HPI;” and (3) “Callanish, together with Scotia Pharmaceuticals Ltd[.], and Quantanova, Canada, Ltd., used different invoices for the same shipment, an invoice accurately identifying the merchandise as EPO was sent to HPI, and a second invoice was sent to Mr. Lockard’s companies, Pine Lawn Farms or Genesis II, which disguised the EPO in the shipments.” Am. Compl. ¶ 16. Plaintiff claims that the documents submitted to Customs for the fifty-two consumption entries of EPO “contained materially false statements,” *1426 Am. Compl. ¶¶ 19-22, and that “Callanish shipped the EPO with knowledge that the importation of the EPO into the United States was illegal and that the EPO would be entered under cover of false documents,” Am. Compl. ¶ 24.

B. Procedural History

The procedural background of this litigation is presented in the court’s opinion and order in United States v. Scotia Pharmaceuti calsLtd., 33 CIT _, _, Slip Op. 09-49, at 4-6, and is further supplemented herein.

On May 20, 2009, the court held that plaintiff had not established its entitlement to the judgment by default that it then sought against defendant Callanish for a civil penalty under 19 U.S.C. § 1592. United States v. Scotia Pharmaceuticals Ltd., 33 CIT at _, Slip Op. 09 — 49, at 13-14. The court denied plaintiff’s application for default but also allowed plaintiff the opportunity to amend its complaint. Id. at Slip Op. 09-49, at 14. Because plaintiff had not effected service upon defendants Scotia Pharmaceuticals and Quantanova, the court granted plaintiff’s request to dismiss the action as to those defendants. Id.

On July 31, 2009, plaintiff filed its amended complaint. Am. Compl. On May 17, 2010, after plaintiff successfully effected service of process úpon Callanish, defendant again failed to appear by licensed counsel and failed to plead or otherwise defend itself within twenty days of being served with the summons and amended complaint, and the Clerk of this Court, pursuant to USCIT Rules 12 and 55, entered Callanish’s default. Pl.’s Req. for Default J. 1; Entry of Default 1.

On May 19, 2010, plaintiff applied for a judgment by default against Callanish pursuant to USCIT Rule 55(b). Pl.’s Req. for Default J. 1. Plaintiff seeks a penalty equal to what it alleges to be the domestic value of the EPO entered on the fifty-two entries, $17,734,926. Id. 2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
34 Ct. Int'l Trade 1423, 2010 CIT 124, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-callanish-ltd-cit-2010.